Etanercept

Subcutaneous TNF inhibitors and their biosimilars are discontinued due to inefficacy and adverse events at similar rates in patients with rheumatic diseases, according to data from Spain published in The Journal of Rheumatology.

The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has announced.

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

Serious infections were uncommon among patients with psoriatic arthritis exposed to targeted therapies for the first time in “a large and exhaustive” French cohort, according to data published in RMD Open.

In this video, Maria Danila, MD, discusses recent advancements in rheumatoid arthritis.

In this edition, difficult-to-treat psoriatic arthritis 'not all about the therapies', Samsung biosimilar comparable to etanercept and more.

Patients with psoriatic arthritis demonstrated similar disease activity outcomes and drug persistence after long-term treatment with either etanercept or its biosimilar SB4, according to data published in Arthritis Care & Research.

Following HHS’ blockbuster announcement of the first 10 drugs that would be subject to Medicare price negotiations, patients and providers alike have been looking forward to meaningful reductions in their costly treatments.

The first 10 drugs eligible for price negotiation through Medicare includes etanercept and ustekinumab, biologic therapies commonly used to treat patients with rheumatic diseases, the Biden administration announced.

Patients with rheumatoid arthritis who demonstrate lower disease activity are more likely to remain in LDA or remission after switching from combination therapy to monotherapy, according to data published in the Journal of Rheumatology.